Terns Pharmaceuticals announced positive results from its Phase 1 trial of TERN-601, showing a maximum placebo-adjusted weight loss of 4.9% at the highest dose, with 67% of participants losing 5% or more of their baseline weight, and plans to advance to Phase 2 in 2025.